Month: April 2021

CALGARY, Alberta, April 09, 2021 (GLOBE NEWSWIRE) — PHX Energy Services Corp. (“PHX Energy” or the “Corporation“) (TSX: PHX) announces that its Board of Directors (the “Board”) has approved a $10 million increase to the Corporation’s 2021 capital expenditure program (the “2021 Program”) and anticipates allocating $8 million of this increase towards growth capital and $2 million towards maintenance. With this increase the Corporation now anticipates spending $25 million in capital expenditures during the 2021-year. PHX Energy expects to dedicate the additional capital expenditures to the growth of the Velocity Real Time System (“Velocity”) and Atlas high performance drilling motor (“Atlas”) fleets. In the first quarter of 2021, the Corporation has experienced an uptick in activity from the last quarter of...

— Fourth Quarter Total Loan Origination Volume grew YoY6.5% to RMB3,088 million—— Fourth Quarter Net Income grew YoY258.8% to RMB81.1 million– SHANGHAI, China, April 09, 2021 (GLOBE NEWSWIRE) — Jiayin Group Inc. (“Jiayin” or the “Company”) (NASDAQ: JFIN), a leading fintech platform in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2020. Fourth Quarter 2020 Operational and Financial Highlights :Loan origination volume2 was RMB3,088 million (US$473.3 million), representing an increase of 6.5% from the same period of 2019, and a decrease of 7.3% sequentially. Average borrowing amount per borrower was RMB6,532 (US$1,001), representing a decrease of 18.8% from the same period of 2019. Repeat borrowing rate3 was 70.4%, compared with repeat borrowing rate...

CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, will present preclinical findings supporting the company’s lead product programs, SRF388 (targeting IL-27) and SRF617 (targeting CD39). These data will be presented as part of the American Association for Cancer Research (AACR) 2021 Annual Meeting, which is being held virtually April 10-15 and May 17-21, 2021. “These findings further support the biological rationale that both of our lead product candidates, SRF388 and SRF617, promote increased proinflammatory activity within the tumor microenvironment in the hopes of ultimately providing novel treatment options to patients with cancer,” said Vito Palombella, chief scientific...

BEIJING, April 09, 2021 (GLOBE NEWSWIRE) — 36Kr Holdings Inc. (“36Kr” or the “Company” or “We”) (NASDAQ: KRKR), a prominent brand and a pioneering platform dedicated to serving New Economy participants in China, today announced that it will report its fourth quarter and fiscal year 2020 unaudited financial results, on Thursday, April 15, 2021, before the open of U.S. markets. The Company’s management will host an earnings conference call at 8:00 AM U.S. Eastern Time on April 15, 2021 (8:00 PM Beijing/Hong Kong Time on April 15, 2021). Details for the conference call are as follows: All participants must use the link provided above to complete the online registration process at least 20 minutes in advance of the conference call. Upon registering, each participant will receive a set of participant dial-in number, Direct Event passcode,...

STOCKHOLM, SWEDEN – April 9, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Aprea Therapeutics’ drug candidate eprenetapopt for the treatment of acute myeloid leukemia (AML). KDev Investments, a company jointly owned by Karolinska Development and Rosetta Capital, holds 8 percent of the shares in Aprea Therapeutics, which is listed on Nasdaq Global Select Market in the USA. Eprenetapopt is a small molecule targeting the tumor suppressor protein p53. Mutations of the p53 gene occur in around 50% of all human tumors and are associated with poor overall survival.The drug candidate is currently being investigated in clinical trials as a potential treatment of hematologic malignancies and solid tumors. In November 2020, the FDA...

STOCKHOLM, SVERIGE 9 april 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att den amerikanska läkemedelsmyndigheten FDA har beviljat särläkemedelsstatus för Aprea Therapeutics läkemedelskandidat eprenetapopt som behandling av akut myeloisk leukemi (AML). KDev Investments, ett bolag vilket ägs gemensamt av Karolinska Development och Rosetta Capital, innehar 8 procent av aktierna i Aprea Therapeutics, som är noterat på Nasdaq Global Select Market i USA. Eprenetapopt är en småmolekylär läkemedelskandidat som riktar sin verkan mot det tumörhämmande proteinet p53. Mutationer i p53-genen förekommer i cirka 50% av alla humana tumörer och är associerade med dålig generell sjukdomsöverlevnad. Läkemedelskandidaten studeras för närvarande i kliniska prövningar som en potentiell behandling av hematologiska maligniteter och...

Herved indkaldes til ordinær generalforsamling i Kapitalforeningen Accunia Invest Ret til at deltage i og afgive stemmer på generalforsamlingen er betinget af, at man besidder andele i foreningen mindst 5 bankdage før datoen for generalforsamlingens afholdelse, dvs. onsdag den 21. april 2021. Dagsorden med fuldstændige forslag og tilhørende bilag, herunder årsrapport for 2020 med tilhørende revisionspåtegning, vil være fremlagt til eftersyn på foreningens kontor fra og med . 12. april 2021 samt være tilgængelige på accunia.com fra samme dato. • Accunia Invest EUR CLO Opportunity KL, ACAECO, DK0060804052• Accunia Invest EUR CLO Invest Grade DKK, ACACIGDKK, DK0060804136• Accunia Invest European High Yield (KL), ACKEHY, DK0061149036 Dagsorden er vedhæftet. Kontaktperson: Direktør Caspar Møller, tlf. +45 3332 7070Yderligere oplysninger om...

SOUTH SAN FRANCISCO, Californie, 09 avr. 2021 (GLOBE NEWSWIRE) — Global Blood Therapeutics, Inc. (GBT) (NASDAQ : GBT) a annoncé aujourd’hui que The Lancet Haematology a publié l’analyse complète des données sur 72 semaines issues de l’étude HOPE de phase 3 sur les comprimés d’Oxbryta® (voxelotor) chez les patients atteints de drépanocytose (SCD). Les résultats ont montré une amélioration significative et soutenue des taux d’hémoglobine, une réduction de l’hémolyse et une amélioration de l’état de santé global chez les patients traités avec Oxbryta. Ces résultats soutiennent l’utilisation à long terme d’Oxbryta pour réduire l’anémie hémolytique et l’hémolyse dans la drépanocytose, réduisant potentiellement les complications parfois mortelles de la maladie. Oxbryta,...